The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Pharmacokinetic profile of imipenem/cilastatin in normal volunteers.

Imipenem is a new carbapenem antibiotic. It is coadministered with an equal amount of cilastatin, a dehydropeptidase-I inhibitor. Both drugs achieve similar serum concentrations in normal volunteers. Half-lives for both drugs are on the order of one hour and are excreted in the main into the urine. Cilastatin has been documented to have a metabolite, N-acetyl cilastatin, which can be recovered in the urine in an amount equivalent to approximately 12 percent of the administered dose of the parent compound. Less than 1 percent of a radiolabeled dose of either compound can be recovered in the feces, making clinically significant alterations of the fecal flora unlikely with the imipenem/cilastatin combination. Although probenecid causes only a minor effect on imipenem pharmacology, it increases the area under the curve and half-life of imipenem and decreases the renal clearance of cilastatin significantly. In view of the pharmacokinetic profile of imipenem/cilastatin, the microbiologic activity of imipenem, and the post-antibiotic effect of imipenem against Pseudomonas aeruginosa, imipenem/cilastatin has the potential to control the majority of bacteremic nosocomial pathogens.[1]


  1. Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Drusano, G.L., Standiford, H.C. Am. J. Med. (1985) [Pubmed]
WikiGenes - Universities